MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC-Reference-Cited by-同舟云学术

MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC

Published:2023-11 Issue: Volume: Page:
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Haratake Naoki,Ozawa Hiroki,Morimoto Yoshihiro,Yamashita Nami,Daimon Tatsuaki,Bhattacharya Atrayee,Wang Keyi,Nakashoji Ayako,Isozaki Hideko,Shimokawa Mototsugu,Kikutake Chie,Suyama Mikita,Hashinokuchi Asato,Takada Kazuki,Takenaka Tomoyoshi,Yoshizumi Tomoharu,Mitsudomi Tetsuya,Hata Aaron N.,Kufe Donald

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference57 articles.

1. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat Rev Cancer,2007

2. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors;Sequist;Sci Transl Med,2011

3. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models;Li;Oncogene,2008

4. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial;Miller;Lancet Oncol,2012

5. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer;Cross;Cancer Discov,2014

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies for enhancing non-small cell lung cancer treatment: Integrating Chinese herbal medicines with epidermal growth factor receptor-tyrosine kinase inhibitors therapy;European Journal of Pharmacology;2024-10

2. MUC1-C Dependence for the Progression of Pancreatic Neuroendocrine Tumors Identifies a Druggable Target for the Treatment of This Rare Cancer;Biomedicines;2024-07-08

3. Emerging paradigms and recent progress in targeting ErbB in cancers;Trends in Pharmacological Sciences;2024-06

4. MUC1-C: The Occam Razor of Osimertinib Resistance?;Journal of Thoracic Oncology;2024-03

5. MUC1-C is a target of salinomycin in inducing ferroptosis of cancer stem cells;Cell Death Discovery;2024-01-05